Circulant matrix

Calibre Intercepts High-Grade Gold & Silver Mineralization from Several Targets at its Eastern Borosi Mine Complex; Drilling Intersects Include 10.81 g/t Gold over 3.4 metres, 9.64 g/t Gold over 3.3 metres, 1,431.6 g/t Silver over 2.9 metres and 642.3 g/t

Retrieved on: 
Monday, April 15, 2024
CXB, Silver, Element, OTCQX, Bureau Veritas, News, Environmental resource management, Resource, Biophysical environment, TSX, QA/QC, Quality, National Instrument 43-101, ICP, Quality management system, Circulant matrix, SAS, National instrument, ISO14001, ETW, Vein, Mining, Hymenaea courbaril, Rope

6.87 g/t Au over 7.0 metres Estimated True Width (“ETW”) including 19.80 g/t Au over 1.1 metres ETW and 6.08 g/t Au over 3.8 metres ETW in Hole BL-23-118;

Key Points: 
  • 6.87 g/t Au over 7.0 metres Estimated True Width (“ETW”) including 19.80 g/t Au over 1.1 metres ETW and 6.08 g/t Au over 3.8 metres ETW in Hole BL-23-118;
    5.72 g/t Au over 8.9 metres ETW including 8.21 g/t Au over 4.8 metres ETW and 7.50 g/t Au over 1.3 metres ETW in Hole BL-23-131;
    8.46 g/t Au over 5.8 metres ETW including 14.80 g/t Au over 2.9 metres ETW in Hole BL-23-133;
    7.06 g/t Au over 17.7 metres ETW including 14.70 g/t Au over 3.3 metres ETW and 12.69 g/t Au over 3.4 metres ETW and 8.92 g/t Au over 2.3 metres ETW in Hole BL-23-136;
    10.81 g/t Au over 3.4 metres ETW including 19.10 g/t Au over 1.8 metres ETW in Hole BL-23-143;
    9.64 g/t Au over 3.3 metres ETW in Hole BL-16-044; and
    5.77 g/t Au over 14.5 metres ETW including 14.00 g/t Au over 3.8 metres ETW and 10.00 g/t Au over 2.2 metres ETW in Hole GTH-BL-23-006.
  • 1,431.6 g/t Ag over 2.9 metres ETW including 1,240.5 g/t Ag over 1.4 metres ETW in Hole BL-15-018;
    642.3 g/t Ag over 5.0 metres ETW including 1,014 g/t Ag over 2.0 metres ETW in Hole BL-15-017;
    401.8 g/t Ag over 3.5 metres ETW including 925.0 g/t Ag over 1.3 metres ETW in Hole BL-23-111;
    318.1 g/t Ag over 1.5 metres ETW in Hole BL-23-112;
    307.3 g/t Ag over 2.7 metres ETW in Hole BL-23-115;
    227.0 g/t Ag over 9.0 metres ETW including 247.8 g/t Ag over 4.8 metres ETW and 437.0 g/t Ag over 1.3 metres ETW in Hole BL-23-131; and
    181.9 g/t Ag over 2.8 metres ETW including 288.5 g/t Ag over 1.7 metres ETW and 162.6 g/t Ag over 5.8 metres ETW including 225.2 g/t Ag over 2.9 metres ETW in Hole BL-23-133.
  • Note: Estimated True Widths for reported vein intercepts are based on 3D models of individual veins.
  • Prior to analysis, samples are prepared at Veritas’s Managua facility and then shipped to its analytical facility in Vancouver, Canada.

Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Elixir, Peripheral artery disease, CLTI, Medicine, Risk, Patient, PAD, Mortality, Motion, Life, BTK, Amputation, Marketing, FDA, Circulant matrix, Food, Pharmaceutical industry

The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.

Key Points: 
  • The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.
  • "The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” said Motasim Sirhan, CEO at Elixir Medical.
  • “We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.”
    The FDA Breakthrough Device Designation accelerates the review process for novel technologies designed to address an unmet medical need.
  • Devices that receive breakthrough designation must meet rigorous standards for device safety and effectiveness in order to be authorized for marketing.

ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round

Retrieved on: 
Monday, March 18, 2024
Health Technology, Health, Medical Devices, Cardiology, Tricuspid valve, Trust, Patient, Circulant matrix, University, Section, Interventional cardiology

ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.

Key Points: 
  • ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
  • Multiple investment funds participated in the round including Unorthodox Ventures, SCP Ventures, WS Investment Company, and individual angel investors.
  • “ConKay’s innovative technology addresses a significant unmet need experienced by tens of millions of patients,” said Unorthodox Ventures Founder Carey Smith.
  • Albert Yuan, Founder and CEO of ConKay Medical, shared, "Millions of Tricuspid Regurgitation patients worldwide are currently left with no medical options and at ConKay, our mission is to help patients live longer lives with their loved ones.

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

Retrieved on: 
Thursday, February 22, 2024
Software, Research, General Health, Data Management, Medical Devices, Technology, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, CCTA, Circulant matrix, MD, Physician, Pathology, Food, FFR, American Medical Association, Food and Drug Administration, Patient, Diagnosis, Category, Coronary artery disease, Medical imaging

The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.

Key Points: 
  • The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.
  • The Category I CPT® code is an addition to the Category III CPT® codes (CPT® 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronary atherosclerosis analysis.
  • “The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease,” said James P. Earls, MD, Chief Medical Officer of Cleerly.
  • The application of Cleerly ISCHEMIA supports improvements in physician certainty, guides medical therapy decision making, and reduces unnecessary invasive and non-invasive testing2-6.

Children’s Hospital Los Angeles Unveils New Fetal Cardiac Clinic

Retrieved on: 
Tuesday, February 13, 2024
Nursing, Cardiology, Children, Baby, Maternity, Health, General Health, Family, Hospitals, Surgery, Consumer, Parenting, Master of Science, Division, CHLA, Multimedia, MSN, RN, Magnetic resonance imaging, CCRN, Ventricular septal defect, Pregnancy, Learning, Child, Risk, MHA, FRCPC, Circulant matrix, MHO, Patient, Senior counsel, Social, Heart, Diagnosis, Test management, MRI, Hospital

Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.

Key Points: 
  • Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240213588362/en/
    The Heart Institute at Children's Hospital Los Angeles celebrates the opening of its new Fetal Cardiac Clinic.
  • “With the launch of our new Fetal Cardiac Clinic, we now have a dedicated space that can serve as a one-stop shop for families in need of comprehensive prenatal diagnostic testing and counseling for cardiac anomalies.”
    CHLA’s state-of-the-art Fetal Cardiac Clinic features over 3,000 square feet of space and three scanning rooms dedicated to fetal cardiology.
  • Services provided at the CHLA Fetal Cardiac Clinic include:
    To learn more about CHLA’s Fetal Cardiac Clinic, visit CHLA.org/FetalCardiology or call 323-361-7398.

New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions

Retrieved on: 
Friday, July 28, 2023
CT, Plaque, Society, Multifocal stenosing ulceration of the small intestine, Anatomy, Society of Cardiovascular Computed Tomography, CAD, Circulant matrix, CCTA, Physiology, Roadmap, IVUS, FFR, Calcium, SCCT, Patient, Risk, Atherosclerosis, Conference, Medical imaging, Pharmaceutical industry

MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.

Key Points: 
  • MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.
  • HeartFlow is the first company to offer a suite of technologies to help clinicians non-invasively identify stenoses in the coronary arteries ( RoadMap™Analysis ), assess coronary blood flow ( FFR C T Analysis ), and characterize and quantify coronary atherosclerosis ( Plaque Analysis ).
  • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools, allowing clinicians to see the full picture of their patients’ coronary artery disease (CAD).
  • "Until now, clinicians have not had access to a complete view of a patient’s heart health with accurate data on coronary anatomy, physiology, and plaque.

Samsung Introduces Premium Women’s Health Ultrasound

Retrieved on: 
Wednesday, February 8, 2023
Hardware, Health Technology, Data Management, Other Health, Technology, Radiology, General Health, Medical Devices, Women, Hospitals, Baby, Maternity, Wearables, Mobile Technology, Other Technology, Consumer, Health, Society, Woman, Circulant matrix, 2D, Samsung, Diagnosis, Artificial intelligence, Sale, Maternal–fetal medicine, FDA, HERA, Multimedia, Gynaecology, Obstetrics, 3D, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20230208005629/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230208005629/en/
    The HERA W10 Elite features an ergonomic-friendly design and is optimized with updated imaging capabilities to drive diagnostic confidence.
  • (Photo: Business Wire)
    “Women’s health is a fast-growing field that requires state-of-the-art equipment for patient care.
  • The HERA W10 Elite will bring visionary change to Obstetrics and Gynecology with sophisticated image processing and an ergonomic-friendly design,” said Tracy Bury, Women's Health Ultrasound Business Leader, Boston Imaging.
  • Samsung is committed to bringing new and updated women’s health-focused ultrasound systems to market to remain true to its pledge to support the life-long healthcare of women.

Cincinnati Children's Opens First-of-its-Kind Heart and Mind Wellbeing Center in United States

Retrieved on: 
Tuesday, January 24, 2023
AHA, Science, American Heart Association, Cincinnati Children's Hospital Medical Center, Diagnosis, Hope, Circulant matrix, Ventricular septal defect, Birth defect, CHD, Partnership, The American Heart Institute, Social, Research, Congenital heart defect, Heart, Acute stress disorder, Parent, Patient, Anxiety, Depression, Multimedia, Doctor of Philosophy, Mental health, Pharmaceutical industry, Nursing

CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Cincinnati Children's Hospital Medical Center is excited to announce the opening of its Heart and Mind Wellbeing Center , the first of its kind in the United States.

Key Points: 
  • CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Cincinnati Children's Hospital Medical Center is excited to announce the opening of its Heart and Mind Wellbeing Center , the first of its kind in the United States.
  • The Heart and Mind Wellbeing Center was created to provide comprehensive psychological support and mental health care tailored for families affected by Congenital Heart Disease (CHD) .
  • "Congenital heart disease can profoundly affect families emotionally," said Nadine Kasparian, PhD , psychologist and director of Cincinnati Children's Heart and Mind Wellbeing Center.
  • Research is also an integral part of the Heart and Mind Wellbeing Center, which is conducting groundbreaking research into parent mental health in conjunction with the Heart Institute's Fetal Heart Program at Cincinnati Children's.